SynthesisClinical journal of the American Society of Nephrology : CJASN2011
Metabolic syndrome and kidney disease: a systematic review and meta-analysis.
Synthesis in Clinical journal of the American Society of Nephrology : CJASN, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04482153 (Prevalence of Non-alcoholic Fatty Liver Disease in Patients With Chronic Kidney Disease in Assiut University Hospitals), which is not on this map. Cited by 309 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Prevalence of Non-alcoholic Fatty Liver Disease in Patients With Chronic Kidney Disease in Assiut University Hospitals
Who cites it
309 citing papers in PubMed, 6 syntheses or guidelines pooled it, 554 citations in OpenAlex.
- Association between dietary inflammatory index and risk of chronic kidney disease and low glomerular filtration rate; a systematic review and meta-analysis of observational studies.Journal of health, population, and nutrition · 2025Pooled it
- The risk of kidney dysfunction in metabolically healthy/unhealthy population with normal weight or overweight/obesity: a systematic review and meta-analysis.Eating and weight disorders : EWD · 2024Pooled it
- Burden of metabolic syndrome in the global adult HIV-infected population: a systematic review and meta-analysis.BMC public health · 2024Pooled it
- Endoscopic Bariatric and Metabolic Therapies and Their Effects on Metabolic Syndrome and Non-alcoholic Fatty Liver Disease - A Systematic Review and Meta-Analysis.Frontiers in medicine · 2022Pooled it
- Modifiable Lifestyle Factors for Primary Prevention of CKD: A Systematic Review and Meta-Analysis.Journal of the American Society of Nephrology : JASN · 2021Pooled it
- Urolithiasis, Independent of Uric Acid, Increased Risk of Coronary Artery and Carotid Atherosclerosis: A Meta-Analysis of Observational Studies.BioMed research international · 2020Pooled it
- Cardiometabolic risk burden and kidney function in middle-aged and older adults: evidence from two national, cross-sectional studies in China and the United States.Renal failure · 2026Article
- Multi-trajectories of serum uric acid/high density lipoprotein cholesterol ratio and fasting plasma glucose in chronic kidney disease.Annals of medicine · 2026Article
- Association of cholesterol, high-density lipoprotein, and glucose index and modified indices in predicting cardiovascular diseases incidence among population with cardiovascular-kidney-metabolic syndrome stages 0-3: a nationwide prospective cohort study.BMC cardiovascular disorders · 2026Article
- Early signs of nephropathy in adolescents with obesity.International journal of obesity (2005) · 2026Article
- Association between different metabolic phenotypes and chronic kidney disease risk: a cohort study.Diabetology & metabolic syndrome · 2026Article
- Long-term mortality trends and disparities in renal failure across the United States, 1999 to 2024: A nationwide population-based ecological time-trend study.The Journal of international medical research · 2026Article
- The global cardiovascular-liver-metabolic syndemic: epidemiology, trends and challenges.Nature reviews. Cardiology · 2026Review
- Associations of Socioeconomic Status With Cardiorenal Metabolic Multimorbidity: Evidence From the UK Biobank Cohort.JACC. Advances · 2026Article
- Atherogenic index of plasma and lower estimated glomerular filtration rate in IgA nephropathy.Lipids in health and disease · 2026Article
- Protective Effects of Chitosan and Rosuvastatin on Renal Structure and Lipid Metabolism in Rabbits Fed a High-Fat Diet.Medicina (Kaunas, Lithuania) · 2026Article
- Incidence of Chronic Kidney Disease According to Steatotic Liver Disease and Its Subclassifications: A Longitudinal Cohort Study.Gut and liver · 2026Article
- Sex-specific associations between annual kidney function changes and weight/waist changes in overweight Japanese: Japan Specific Health Checkup cohort.Endocrine journal · 2026Article
- Association of MASLD with chronic kidney disease according to metabolic profiles and fibrosis severity: a KNHANES analysis.Frontiers in endocrinology · 2026Article
- Different Stages of Cardiovascular-Kidney-Metabolic Syndrome Associated With the Risk of All-Cause and Cause-Specific Mortality: Insights From Two Prospective Cohort Studies.International journal of endocrinology · 2026Article
249 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
Abstract
BACKGROUND AND
objectivesObservational studies have reported an association between metabolic syndrome (MetS) and microalbuminuria or proteinuria and chronic kidney disease (CKD) with varying risk estimates. We aimed to systematically review the association between MetS, its components, and development of microalbuminuria or proteinuria and CKD. DESIGN, SETTING, PARTICIPANTS AND MEASUREMENTS AND POPULATION: We searched MEDLINE (1966 to October 2010), SCOPUS, and the Web of Science for prospective cohort confidence interval (CI) studies that reported the development of microalbuminuria or proteinuria and/or CKD in participants with MetS. Risk estimates for eGFR <60 ml/min per 1.73 m(2) were extracted from individual studies and pooled using a random effects model. The results for proteinuria outcomes were not pooled because of the small number of studies.
resultsEleven studies (n = 30,146) were included. MetS was significantly associated with the development of eGFR <60 ml/min per 1.73 m(2) (odds ratio, 1.55; 95% CI, 1.34, 1.80). The strength of this association seemed to increase as the number of components of MetS increased (trend P value = 0.02). In patients with MetS, the odds ratios (95% CI) for development of eGFR <60 ml/min per 1.73 m(2) for individual components of MetS were: elevated blood pressure 1.61 (1.29, 2.01), elevated triglycerides 1.27 (1.11, 1.46), low HDL cholesterol 1.23 (1.12, 1.36), abdominal obesity 1.19 (1.05, 1.34), and impaired fasting glucose 1.14 (1.03, 1.26). Three studies reported an increased risk for development of microalbuminuria or overt proteinuria with MetS.
conclusionsMetS and its components are associated with the development of eGFR <60 ml/min per 1.73 m(2) and microalbuminuria or overt proteinuria.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.